Whether you’re a cutting-edge medical device startup or a global biopharma leader, it’s mission that drives you. Amid pricing and payor pressures, regulatory scrutiny, emerging innovations and challenging pipelines, market demand continues to grow. To broaden your field of vision as you navigate this dynamic industry, you need integrated, global counsel that can help clear your path to success.
McDermott’s Life Sciences Team will get you closer to your goals. Composed of top lawyers with demonstrated strength across intellectual property, regulatory, transactional and litigation law, we’re a purpose-built team of thought leaders united by a passion for our work. Our team can meet the legal needs of life sciences companies at every stage of development. For decades, we have embraced the value of focused knowledge, harnessing both the particular skills of individuals and the collective experience of our team. This makes us uniquely qualified to help you move business initiatives across the finish line when it matters and anticipate what’s next.
Practicing across the North America, Europe and Asia, our team is steeped in experience gained from prior service as in-house counsel for leading life sciences companies and as senior leaders within government agencies, including the US Food and Drug Administration, Federal Trade Commission, Department of Health and Human Services and Department of Justice. Combined with lawyers from our top-ranked health law practice, we work at the juncture of health, technology and life sciences, and understand the issues that matter when it comes to achieving your mission and solidifying your position in the market.
Eli Lilly and Company (NYSE: LLY) with multiple transactions, including the acquisitions of Pacific Biotech Inc. for $135 million and Devices for Vascular Intervention Inc. for $120 million
TOLMAR Inc., with a complete defense victory, in an ANDA case in the US District Court for the District of Delaware, where TOLMAR was first to file an ANDA for a generic calcipotriene cream product for the treatment of psoriasis and as a result of the process the plaintiff voluntarily dismissed its case allowing TOLMAR to immediately bring to market its generic product.
Amgen Inc., the world’s largest biotech company, with securing a motion to dismiss before the US Court of Appeals for the Third Circuit in a high stakes, class action antitrust case brought by Warren General Hospital, alleging that Amgen had illegally tied sales of its blockbuster drugs, Neulasta® and Neupogen®, with another of its drugs
Nexus Pharmaceuticals, Inc., a US-based company specializing in the development of generic injectable and ophthalmic drugs, in the sale of multiple ANDAs to Rising Pharmaceuticals, Inc.
Seikagaku Corporation in its licensing agreement with the University of British Columbia for its recombinant means of producing limulus-derived lysates
Volution Immuno Pharmaceuticals SA with its combination with UK-based Akari Therapeutics plc (NASDAQ: AKTX), formerly known as Celsus Therapeutics plc (NASDAQ: CLTX)
A $12 billion global healthcare products leader with its global trademark, clearance, protection and enforcement, and in corporate transactional matters affecting intellectual property
A Chinese pharmaceutical company in its daily legal matters including: conducting contract reviews and legal compliance, structuring its business model and negotiating on its behalf with a counterparty in producing a new API, as well as with various overseas funds in relation to its oversea financing, mergers and acquisitions
McDermott’s Life Sciences Team will get you closer to your goals. Composed of top lawyers with demonstrated strength across intellectual property, regulatory, transactional and litigation law, we’re a purpose-built team of thought leaders united by a passion for our work.